Omnicell (OMCL)
(Delayed Data from NSDQ)
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
Omnicell's Aesynt Buyout Looks Promising amid Several Woes
by Zacks Equity Research
On Apr 6, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Why Is Omnicell (OMCL) Up 3% Since the Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise
by Zacks Equity Research
On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.
Omnicell Partners with DCH Health for Sterile Compounding
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.
Omnicell Unveils XT Series Automated Dispensing System
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently introduced a new generation of medication and supply automation that is fully integrated with the company's Unity enterprise platform -- XT series.
Omnicell to Buy Ateb, Expand in Adherence Tools Market
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently inked a deal to buy pharmacy-based patient care solution provider Ateb, Inc and its Canadian affiliate, Ateb Canada Ltd.